Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial

Chollet, François; Tardy, J.; Albucher, Jean‐François; Thalamas, Claire; Bérard, Emilie; Lamy, Catherine; Béjot, Yannick; Deltour, Sandrine; Jaillard, Assia; Niclot, Philippe; Guillon, Benoı̂t; Moulin, Thierry; Marqué, P.; Pariente, Jérémie; Arnaud, Catherine; Loubinoux, Isabelle

doi:10.1016/s1474-4422(10)70314-8

Cited by 800 publications

(615 citation statements)

References 29 publications

Supporting

Mentioning

585

Contrasting

Unclassified

Order By: Relevance

“…Likewise, these results are in agreement with the efficacy of selective serotonin reuptake inhibitors in neurofunctional recovery of nondepressed patients with recent stroke. 8,9,38,39 Summary and Conclusions In summary, we report here for the first time the PET imaging of serotoninergic system using both [ 11 C]DASB and [ 18 F]altanserin and its relationship with the functional recovery after transient focal cerebral ischemia in rats. These results showed a long-term increase in ipsilateral [ 11 C]DASB uptake in the ipsilateral midbrain raphe nuclei and a dramatic decrease in both [ 11 C]DASB and [ 18 F]altanserin in ischemic cortex and striatum.…”

Section: Serotoninergic Changes After Cerebral Ischemiamentioning

confidence: 80%

“…8,9 Thus, as these findings suggest a key role of serotoninergic neurotransmission in functional recovery after stroke, we sought to evaluate the serotoninergic neurotransmission evolution by using PET after focal cerebral ischemia in rats.…”

Section: Serotoninergic Changes After Cerebral Ischemiamentioning

confidence: 99%

“…6 Likewise, clinical studies have shown that the use of pharmacological therapies that increase brain concentrations of brain amines such as dopamine and serotonin promotes a positive impact on stroke outcomes. 7 Moreover, the modulation of serotoninergic neurotransmission by using selective serotonin reuptake inhibitors such as fluoxetine and citalopram improved motor and cognitive recovery in both the clinic 8,9 and the laboratory. 10 Positron emission tomography (PET) with [ 11 C]DASB and [ 18 F]altanserin has widely been used to investigate the availability of serotonin transporter (SERT) and serotonin receptor 5-HT 2A in both humans and animals.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PET Imaging of Serotoninergic Neurotransmission with [¹¹C]DASB and [¹⁸F]altanserin after Focal Cerebral Ischemia in Rats

Martín

Szczupak

Gómez‐Vallejo

et al. 2013

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

The use of selective serotonin reuptake inhibitors has shown functional improvement after stroke. Despite this, the role of serotoninergic neurotransmission after cerebral ischemia evolution and its involvement in functional recovery processes are still largely unknown. For this purpose, we performed in parallel in vivo magnetic resonance imaging and positron emission tomography (PET) with [ 11 C]DASB and [ 18 F]altanserin at 1, 3, 7, 14, 21, and 28 days after middle cerebral artery occlusion (MCAO) in rats. In the ischemic territory, PET with [ 11 C]DASB and [ 18 F]altanserin showed a dramatic decline in serotonin transporter (SERT) and 5-HT 2A binding potential in the cortex and striatum after cerebral ischemia. Interestingly, a slight increase in [ 11 C]DASB binding was observed from days 7 to 21 followed by the uppermost binding at day 28 in the ipsilateral midbrain. In contrast, no changes were observed in the contralateral hemisphere by using both radiotracers. Likewise, both functional and behavior testing showed major impaired outcome at day 1 after ischemia onset followed by a recovery of the sensorimotor function and dexterity from day 21 to day 28 after cerebral ischemia. Taken together, these results might evidence that SERT changes in the midbrain could have a key role in the functional recovery process after cerebral ischemia.

show abstract

Section: Serotoninergic Changes After Cerebral Ischemiamentioning

confidence: 80%

Section: Serotoninergic Changes After Cerebral Ischemiamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PET Imaging of Serotoninergic Neurotransmission with [¹¹C]DASB and [¹⁸F]altanserin after Focal Cerebral Ischemia in Rats

Martín

Szczupak

Gómez‐Vallejo

et al. 2013

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

show abstract

“…Studies show that traditional antidepressants, like the SSRIs, have some benefit for the treatment of PSD [14,15,[103][104][105]. The quality of these studies, however, has been suboptimal and the evidence is not yet compelling enough to suggest that antidepressants be prescribed to all patients with PSD [106].…”

Section: Therapeutic Approaches To the Treatment Of Depression: A Focmentioning

confidence: 99%

Inflammation and the Silent Sequelae of Stroke

Becker

2016

Neurotherapeutics

View full text Add to dashboard Cite

Depression and fatigue are common after stroke and negatively impact the quality of life of stroke survivors. The biological bases of these symptoms are unknown, but an abundance of data point to a role for inflammation. This review highlights evidence supporting the contribution of inflammation to poststroke depression and poststroke fatigue. Potential treatments for poststroke depression and poststroke fatigue are explored, with a special emphasis on those that modulate the immune response.

show abstract

“…For those patients, mirror therapy,6 motor imagery,7, 8 action observation therapy,9 electrical stimulation (e.g., noninvasive brain stimulation,10, 11, 12 or vagus nerve stimulation13) and robot‐aided sensorimotor stimulation14 have been investigated as possible alternatives over the last several years. Driven by advances in other technological areas such as virtual and augmented reality (VR/AR), robotics, invasive and noninvasive brain‐computer interfaces (BCIs),15 as well as pharmacology,16, 17 post‐stroke motor rehabilitation is now a fast growing, emerging field.…”

Section: Introductionmentioning

confidence: 99%

Brain‐computer interfaces for post‐stroke motor rehabilitation: a meta‐analysis

Cervera

Soekadar

Ushiba

et al. 2018

Ann Clin Transl Neurol

316

240

View full text Add to dashboard Cite

Brain‐computer interfaces (BCIs) can provide sensory feedback of ongoing brain oscillations, enabling stroke survivors to modulate their sensorimotor rhythms purposefully. A number of recent clinical studies indicate that repeated use of such BCIs might trigger neurological recovery and hence improvement in motor function. Here, we provide a first meta‐analysis evaluating the clinical effectiveness of BCI‐based post‐stroke motor rehabilitation. Trials were identified using MEDLINE, CENTRAL, PEDro and by inspection of references in several review articles. We selected randomized controlled trials that used BCIs for post‐stroke motor rehabilitation and provided motor impairment scores before and after the intervention. A random‐effects inverse variance method was used to calculate the summary effect size. We initially identified 524 articles and, after removing duplicates, we screened titles and abstracts of 473 articles. We found 26 articles corresponding to BCI clinical trials, of these, there were nine studies that involved a total of 235 post‐stroke survivors that fulfilled the inclusion criterion (randomized controlled trials that examined motor performance as an outcome measure) for the meta‐analysis. Motor improvements, mostly quantified by the upper limb Fugl‐Meyer Assessment (FMA‐UE), exceeded the minimal clinically important difference (MCID=5.25) in six BCI studies, while such improvement was reached only in three control groups. Overall, the BCI training was associated with a standardized mean difference of 0.79 (95% CI: 0.37 to 1.20) in FMA‐UE compared to control conditions, which is in the range of medium to large summary effect size. In addition, several studies indicated BCI‐induced functional and structural neuroplasticity at a subclinical level. This suggests that BCI technology could be an effective intervention for post‐stroke upper limb rehabilitation. However, more studies with larger sample size are required to increase the reliability of these results.

show abstract

Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial

Cited by 800 publications

References 29 publications

PET Imaging of Serotoninergic Neurotransmission with [¹¹C]DASB and [¹⁸F]altanserin after Focal Cerebral Ischemia in Rats

PET Imaging of Serotoninergic Neurotransmission with [¹¹C]DASB and [¹⁸F]altanserin after Focal Cerebral Ischemia in Rats

Inflammation and the Silent Sequelae of Stroke

Brain‐computer interfaces for post‐stroke motor rehabilitation: a meta‐analysis

Contact Info

Product

Resources

About

Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial

Cited by 800 publications

References 29 publications

PET Imaging of Serotoninergic Neurotransmission with [11C]DASB and [18F]altanserin after Focal Cerebral Ischemia in Rats

PET Imaging of Serotoninergic Neurotransmission with [11C]DASB and [18F]altanserin after Focal Cerebral Ischemia in Rats

Inflammation and the Silent Sequelae of Stroke

Brain‐computer interfaces for post‐stroke motor rehabilitation: a meta‐analysis

Contact Info

Product

Resources

About

PET Imaging of Serotoninergic Neurotransmission with [¹¹C]DASB and [¹⁸F]altanserin after Focal Cerebral Ischemia in Rats

PET Imaging of Serotoninergic Neurotransmission with [¹¹C]DASB and [¹⁸F]altanserin after Focal Cerebral Ischemia in Rats